Advertisement

Topics

Concerto HealthAI, Astellas partner on RWE in acute myeloid leukemia

14:41 EDT 10 Apr 2019 | MedCity News

The partnership will focus on using real-world evidence to improve understanding of responses among patients with acute myeloid leukemia whose disease carries mutations in the FLT3 gene. Astellas markets a drug for FLT3-positive AML, Xospata, approved in November.

Original Article: Concerto HealthAI, Astellas partner on RWE in acute myeloid leukemia

NEXT ARTICLE

More From BioPortfolio on "Concerto HealthAI, Astellas partner on RWE in acute myeloid leukemia"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...